Biogen up 5% after EMA recommends Leqembi for early Alzheimer’s disease
The Fly

Biogen up 5% after EMA recommends Leqembi for early Alzheimer’s disease

11:04 EST Biogen (BIIB) up 5% after EMA recommends Leqembi for early Alzheimer’s disease

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App